Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Direct oral anticoagulants: An update
Journal Information
Vol. 151. Issue 5.
Pages 198-206 (September 2018)
Download PDF
More article options
Vol. 151. Issue 5.
Pages 198-206 (September 2018)
Direct oral anticoagulants: An update
Anticoagulantes orales directos: puesta al día
Ana Isabel Franco Moreno
Corresponding author

Corresponding author.
, Rosa María Martín Díaz, María José García Navarro
Servicio de Medicina Interna, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain
Article information
Full Text
Download PDF
Figures (1)
Tables (4)
Table 1. Efficacy and safety of direct oral anticoagulants in phase III clinical trials in the prevention of embolism of cardiac origin in non-valvular atrial fibrillation, in the acute treatment of venous thromboembolism and in secondary prevention of acute coronary syndrome.
Table 2. Approved indications for direct oral anticoagulants and dose regimens.
Table 3. Monitoring methods for direct oral anticoagulants.
Table 4. Drug interactions of direct oral anticoagulants.
Show moreShow less

Vitamin K antagonists were the only choice for chronic oral anticoagulation for more than half a century. Over the past few years, direct oral anticoagulants have emerged, including one direct thrombin inhibitor (dabigatran etexilate) and three factor Xa inhibitors (apixaban, edoxaban and rivaroxaban). In randomized controlled trials comparing direct oral anticoagulants with traditional vitamin K antagonists, the direct oral anticoagulants all showed a favourable benefit-risk balance in their safety and efficacy profile, in prevention of thromboembolic events in patients with atrial fibrillation and in the prevention and treatment of venous thromboembolism and acute coronary syndrome. In 2008, dabigatran was the first direct oral anticoagulant approved by the European Medicine Agency. Subsequently, rivaroxaban, apixaban and edoxaban were also authorized. This article reviews the evidence related to the use of these drugs.

Anticoagulant treatment
Vitamin K antagonists
Dabigatran etexilate

Durante medio siglo los antagonistas de la vitamina K han sido la única opción disponible para la terapia anticoagulante oral. En los últimos años se han desarrollado anticoagulantes orales directos: un inhibidor directo de la trombina (dabigatrán etexilato) y 3 inhibidores directos del factor X activado (rivaroxabán, apixabán y edoxabán). Todos ellos han demostrado un beneficio-riesgo favorable, comparables en eficacia y seguridad a los anticoagulantes tradicionales antagonistas de la vitamina K, en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular, la profilaxis y el tratamiento del tromboembolismo venoso y el síndrome coronario agudo. En 2008 la Agencia Europea del Medicamento aprobó el primer anticoagulante oral directo, dabigatrán. Posteriormente, rivaroxabán, apixabán y edoxabán fueron autorizados. En este artículo se revisa la experiencia acumulada con cada uno de estos fármacos.

Palabras clave:
Tratamiento anticoagulante
Antagonistas de la vitamina K
Dabigatrán etexilato


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos